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Diffusion tensor imaging (DTI) metrics such as Fractional Anisotropy (FA) and Mean 
Diffusivity (MD) have been proposed as clinical trial markers of cerebral small vessel disease 
due to their associations with outcomes such as cognition. However, studies investigating this 
have been predominantly single-centre. As clinical trials are likely to be multi-site, further 
studies are required to determine whether associations with cognition of similar strength can 
be detected in a multi-centre setting. 109 patients (mean age=68) with symptomatic lacunar 
infarction and confluent white matter hyperintensities (WMH) on MRI was recruited across 6 
sites as part of the PRESERVE DTI sub-study. After handling of missing data, 3T-MRI 
scanning was available from 5 sites on 5 scanner models (Siemens and Philips), alongside 
neuropsychological and Quality of Life (QoL) assessments. FA median and MD peak height 
were extracted from DTI histogram analysis. Multiple linear regressions were performed, 
including normalised-brain volume, WMH lesion load, and no lacunes as covariates, to 
investigate the association of FA and MD with cognition and QoL. DTI metrics from all 
white matter were significantly associated with Global Cognition (standardised く=.268), 
Mental Flexibility (く=.306), Verbal Fluency (く=.376), and MoCA (く=.273). The magnitudes 
of these associations were comparable to those previously reported from single-centre studies 
found in a systematic literature review. In this multi-centre study, we confirmed associations 
between DTI parameters and cognition, which were similar in strength to those found in 
previous single-centre studies. This study supports the use of DTI metrics as biomarkers of 




Abbreviations: CABG: Coronary Artery Bypass Graft, CSF: Cerebrospinal Fluid, DSC: Digit 
Symbol Coding, DTI: Diffusion Tensor Imaging, FA: Fractional Anisotropy, FDT: FMRIB 
Diffusion Toolbox, FLAIR: Fluid Attenuated Inversion Recovery, FLIRT: FMRIB Linear 
Image Registration Tool, FSL: FMRIB Software Library, GM: Grey Matter, MD: Mean 
Diffusivity, MoCA: Montreal Cognitive Assessment, NART: National Adult Reading Test, 
NAWM: Normal-Appearing White Matter, NBV: Normalised Brain Volume, RAVLT: Rey 
Auditory Verbal Learning Test, QoL: Quality of Life, SPM: Statistical Parametric Mapping, 
SSQoL: Stroke Specific Quality of Life, SVD: Small Vessel Disease, T1W: T1-Weighted, 
T2*W: T2*-Weighted, TMT: Trail Marking Test, TPM: Tissue Probability Map, WM: (all) 




Cerebral Small Vessel Disease (SVD) causes a quarter of all ischaemic strokes, is the most 
common pathology underlying vascular cognitive impairment and dementia (1), and 
contributes to the severity of Alzheimer’s Disease (2). SVD affects the small vessels of the 
brain and results in a number of characteristic radiological appearances best seen on MRI, 
including lacunar infarcts, T2-white matter hyperintensities (WMH), cerebral microbleeds, 
and brain atrophy (3,4). In terms of symptoms, cognitive impairment may be the most 
debilitating (5), with SVD characteristically associated with early deficits in executive 
function and processing speed, while episodic memory is relatively spared (1,2,6–9).  
Despite the public health importance of SVD, there are few specific treatments (10). 
Furthermore, evaluating treatments represents a major challenge due to the variable rate of 
cognitive decline which can be slow in many patients, but occurs rapidly with progression to 
dementia in a subset. Whilst cognitive testing plays a central role in identifying the presence 
of cognitive impairment, it has proved to be relatively insensitive to longitudinal change (11). 
This has led to the suggestion that MRI might represent a useful surrogate marker to monitor 
disease progression and evaluate the efficacy of therapeutic interventions in smaller patient 
numbers prior to larger phase 3 trials (3,12).  
Diffusion Tensor Imaging (DTI) has been shown to be particularly sensitive to white matter 
damage in SVD. Abnormalities have been shown not only within T2-WMH but also in 
apparently “normal appearing white matter” (13), and these changes correlate better with 
cognition than WMH lesion volume (8). In single-centre studies, change on DTI could be 
detected in SVD patients over follow-up periods of 1 to 3 years (14,15). This has led to the 
suggestion that DTI might provide a useful surrogate marker, and power calculations for 
phase 2 trials based on the rate of DTI change seen in these papers have shown that its use 
may allow evaluation of therapeutic interventions with much smaller samples sizes than if 
cognitive function was used as an outcome measure (11). However, studies conducted to date 
have been single-centre (12,15,16). Most therapeutic trials are likely to be multi-centre and 
involve acquisition of DTI across different sites. As image acquisition will be on different 
scanners this may present challenges (17). It is important to assess whether DTI is feasible in 
a clinical trial setting, and whether similar associations between MRI parameters and clinical 
and cognitive variables can be detected in the multi-centre setting. One way of assessing this 
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is to determine whether the strength of association between DTI and cognition in multi-centre 
studies is similar to that previously reported in single-centre studies.  
To evaluate this we determined the association between DTI parameters and cognition in the 




The PRESERVE study (“How intensively should we treat blood PRESsure in established 
cERebral small VEssel disease?”) is a multi-centre randomised controlled trial comparing a 
strategy of intensive, versus standard, treatment of blood pressure on cognitive function over 
a two year follow-up period. Nested within the overall study is a DTI substudy in which 
patients additionally undergo multimodal MRI including DTI at baseline and at the end of the 
two year follow-up period. The baseline data from these individuals is presented in this paper.  
Study Population 
Inclusion criteria were a clinical lacunar stroke with an anatomically corresponding lacunar 
infarct on MRI, in addition to confluent WMH graded as ≥ 2  on the Fazekas scale (18). 
Patients were at least 40 years old with hypertension defined as either a systolic blood 
pressure >140mmHg, or a systolic blood pressure between 125-140mmHg while on 
antihypertensive treatment. Exclusion criteria were: a known single gene disorder causing 
SVD (e.g. CADASIL), symptomatic carotid stenosis or vertebral stenosis >50% , cortical 
infarction >2cm diameter, diagnosis of dementia, life expectancy of less than two years, 
symptomatic postural hypotension, women of childbearing potential and any inability to fulfil 
study data collection. All patients gave informed written consent. The study was approved by 
the Harrow NRES ethics committee (REC number: 11/LO/0458), and is registered with the 
UK Clinical Research Network (CRN number: 10962). 
109 patients from 6 sites consented to participate in the PRESERVE DTI sub-study. The site 
sample sizes are as follows: Site 1 (N=48), Site 2 (N=29), Site 3 (N=14), Site 4 (N=11), Site 





A stroke physician or vascular neurologist examined all participants. Cerebrovascular risk 
factors including a history of previous stroke, hypercholesterolaemia, diabetes, smoking 
(current and history), angina, myocardial infarction, coronary artery bypass grafts or coronary 
angioplasty were recorded.  
Neuropsychological Assessment 
Cognitive Testing: Assessment was performed by a neuropsychologist and occurred on the 
same day as MRI scanning, or as close to the scan as possible. A cognitive test battery was 
used which included tests sensitive to the characteristic impairments in processing speed and 
executive function associated with SVD (2), with additional testing of memory. This included 
for processing speed the Digit Symbol Coding test (DSC) (19), and for executive functioning 
the Trail Marking Test (TMT, (20)) to measure mental flexibility, and a phonemic verbal 
fluency task (FAS) (21) and a semantic verbal fluency task (animals) (22) to measure verbal 
generativity. Memory was measured using the Rey Auditory Verbal Learning Test (RAVLT, 
(23)). Premorbid IQ was estimated using the restandardised National Adult Reading Test 
(NART-R, (24)) and additional screening for cognitive impairment was conducted using the 
Montreal Cognitive Assessment (MoCA, (25)). 
In addition the following assessments of disability and quality of life were performed; the 
Stroke Specific Quality of Life assessment (SSQoL) (26), and the EuroQoL (27). 
Performance across neuropsychological tests was made comparable by transforming raw 
scores into z-scores using the best available age-scaled normative data (DSC; (19), TMT; 
(28), Letter Fluency; (21), Animal Fluency; (22), RAVLT; (28)). Tasks were grouped into 
four key domains (Processing Speed: WAIS coding total correct, TMT-A time to complete, 
Mental Flexibility: TMT-B time to complete, Verbal Fluency: total correct for “FAS” letter 
fluency and Animal fluency, and Verbal Memory: RAVLT “immediate” and “delayed” 
recall). Individual task z-scores were averaged across these groupings to create overall 
domain scores, while all domain scores were averaged to create a Global Cognition domain. 
SSQoL (total score), EuroQoL (“healthstate” rating) and the MoCA (total score) were 
analysed individually using raw scores. 
Where data were missing due to a subject being unable to complete a task the lowest 
available Z score was given; this applied to 15 individual tasks, across 13 participants (11.9% 
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of the sample size). If data were missing for any other reasons then the domain scores were 
calculated without that task; this applied to 3 participants (2.8% of the sample size). 
Magnetic Resonance Imaging Acquisition 
The aim was to test a study design for which MRI data was acquired using clinical scanners 
in different sites from different manufacturers. Within the 6 centres, 8 3-Tesla MR scanners 
were used (3 Philips Acheiva TX, 1 Philips Acheiva, 1 Philips Ingenia, 1 Siemens Verio, 1 
Siemens Prisma, 1 Siemens Magnetom Prismafit). MRI acquisition included 3D T1-weighted 
(T1W), and DTI, T2*-weighted (T2*W), and Fluid Attenuated Inversion Recovery (FLAIR) 
scans for each participant. A rigorous quality control was implemented to ensure sequence 
acquisition parameters were as standardised as possible. T1W scans were acquired at 1mm3 
isotropic voxel resolution and TR and TE were optimised to ensure comparable T1 weighting 
and tissue contrast across sites. DTI scans (2mm3 isotropic voxel resolution) had similar TEs 
and long TRs to avoid T1 relaxation effects. In addition to the b = 0 s mm-2 acquisitions, all 
DTI acquisition included 32 equally spaced, non-collinear diffusion gradient directions (b = 
1000 s mm-2) to ensure identical angular resolution and noise characteristics. T2*W 
sequences were TE matched and kept a similar TR to ensure comparable weighting. FLAIR 
sequences had identical inversion times and were also TE matched with long enough TR’s to 
ensure no T1 weighting occurred. Resolution for T2*W and FLAIR sequences varied 
between sites; supplementary Table 1 gives an overview of the exact scanner and sequence 
details per site. 
MRI data analysis 
In addition to DTI, measures describing WMH, lacunes and brain volume are frequently 
investigated as potential markers of SVD (8,12,29–31). In the present study, these were 
analysed as a comparison to DTI. 
WMH: WMH were defined as areas of increased signal on FLAIR images (excluding the 
rims of cavitated lacunes), and segmented by a single trained rater (I.D.C.) using a semi-
automated, contouring technique in Jim image analysis software version 7.0_5 (Xinapse 
Systems Limited, http://www.xinapse.com/j-im-7-software/). Whole brain WMH lesions 
maps were generated and a WMH lesion load score was calculated as the percentage of 
WMH lesion volume against whole brain volume. To assess intra- and inter-rater reliability a 
test set of 10 FLAIR scans (from a previous study in SVD) with varying degrees of WMH 
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was used. In a randomised, blinded setting FLAIR images were each marked twice by I.D.C. 
and once by a second experienced rater (D.T.). The intraclass correlation coefficient (32) was 
calculated to assess inter-rater reliability (I.D.C. vs. D.T.) and intra-rater reliability providing 
coefficients of .988 and .998 respectively. 
Lacunes: Lacunes were defined as cerebrospinal fluid (CSF) filled cavities at least 3mm in 
diameter. Additional features such as T2-hyperintense rims, shape and location were also 
considered to differentiate lacunes from similar imaging features such as perivascular spaces. 
The same single rater (I.D.C.) identified lacunes after training by a consultant 
neuroradiologist using a combination of T1W, T2*W and FLAIR scans. 
Brain Volume: T1W scans were intensity non-uniformity corrected using “N4ITK” (33) and 
segmented into grey matter (GM), white matter (WM) and CSF tissue probability maps 
(TPM) using SPM12b (Statistical Parametric Mapping, http://www.fil.ion.ucl.ac.uk/spm/ 
(34)). Brain volume in native space was calculated from the soft segmentation of the GM and 
WM TPMs. 
To obtain brain volume measures sensitive to atrophy, SIENAX ((35), a part of FSL; FMRIB 
Software Library, https://fsl.fmrib.ox.ac.uk/fsl (36)) was applied to T1W scans giving a 
scaling factor that describes the variation of brain size relative to the skull size. The native 
space brain volumes were multiplied by this scaling factor to provide normalised brain 
volumes (NBV). To minimise tissue misclassification of WMH as GM, the (normalised) 
volume of any GM which occurred within WMH was subtracted from the GM volume and 
added to the WM volume. Finally, whole NBV was calculated by adding GM and WM 
NBV’s together. 
DTI Histogram Analysis: FSL software (FDT; FMRIB’s Diffusion Toolbox, 
http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FDT) was used for DTI pre-processing. Briefly; DTI 
scans were eddy current-corrected with eddy_correct using the 1st acquired b = 0 s mm-2 
image as the reference. A binary brain mask in DTI space was calculated for each subject 
using BET on the same b = 0 acquisition. Fractional anisotropy (FA) and mean diffusivity 
(MD) maps were then calculated from these data using DTIFIT. Voxels with MD values 
above 0.0026mm2s-1 were removed from analyses in case of them having been misclassified 
as CSF voxels by application of a diffusivity threshold. Likewise, spurious voxels with FA 
>1 were also removed. For each participant, FMRIB Linear Image Registration Tool (FLIRT, 
(37), using the normalised mutual information cost function in FSL) was used to register the 
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FLAIR to the T1W image, and the T1W to the b0 image (the average of all the b= 0 s mm-2 
images in the DTI sequence). These affine transformation matrices were concatenated to 
create a third FLAIR-to-DTI transformation. TPM’s and WMH lesion masks were registered 
into DTI space using the T1W-to-DTI (trilinear interpolation), and FLAIR-to-DTI (nearest 
neighbour interpolation) transforms for TPMs and binary WMH lesion masks, respectively.  
A hard segmentation method was applied to generate maps of tissue classes. This was 
achieved by voxelwise comparison of the GM, WM and CSF TPMs, with each voxel being 
assigned to the highest probability tissue class. The WMH lesion masks were then added with 
these lesion voxels being automatically assigned to WMH. Finally, mask images of normal-
appearing white matter (NAWM) and all white matter (WM) were generated from the hard 
segmentation map. 
Histogram analysis was performed on FA and MD maps in both NAWM and WM. 
Normalised histograms with 1000 bins (FA range 0-1, bin width 0.001; MD range 0-4mm2s-1 
x10-3, bin width 0.004mm2s-1 x10-3) were computed and median, peak height and peak value 
were extracted from these for both FA and MD. These metrics were chosen as summary 
measures as FA and MD are non-normally distributed in WM. 
Statistical Analyses: All analyses were performed using IBM SPSS statistics version 23 
(IBM Corp. Released 2013. IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp, 
http://www.ibm.com/analytics/us/en/technology/spss/).  
One measure for each MD and FA was chosen for the main study analyses. MD (normalised) 
peak height and FA median were picked due to previous studies which have shown these to 
be correlated with cognition (8,14), and sensitive to change in WM microstructure in SVD 
(11,15).  
To compare MRI with cognitive parameters, “Simple” and “Complex” model linear 
regressions were conducted. This pipeline was structured as a method of selecting the most 
appropriate MRI measure per type (e.g. one brain tissue volume measurement, or MD / FA 
histogram parameter for DTI) so that contributions of MRI metrics could be assessed together 
while avoiding issues of multicollinearity. Thus, in Simple models the association of NBV, 
WMH lesion load, lacunes and histogram parameters (from NAWM and WM) were 
separately investigated against each outcome measure (cognitive domains, QoL and MoCA). 
As there were multiple NBV and DTI variables, the most significant of each type (or if p 
value was the same, the one with the largest く-value), per outcome measure, was selected and 
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used in the Complex model. Here, NBV, WMH lesion load, no lacunes, and DTI measures 
were included together to assess their contributions relative to each other. Separate Complex 
models were performed for each outcome measure, in WM and NAWM. These models 
controlled for confounding effects of age, gender, premorbid IQ, and were stratified by study 
site. Residuals were inspected for normality for all regression analyses while variance 
inflation factors were also calculated for the Complex Models to assess multicollinearity. 
Further analyses compared DTI and outcome variables between sites, and repeated some 
Complex model analyses using site-specific data. These are detailed in the Supplementary 
Analysis. 
Systematic Review: To allow comparison of the results with previous single-centre studies, a 
systematic review of previous literature was conducted on Pubmed 
(https://www.ncbi.nlm.nih.gov/pubmed/) using search terms of “cerebral small vessel disease 
diffusion tensor imaging”, “white matter hyperintensities diffusion tensor imaging”, and 
“leukoaraiosis diffusion tensor imaging” on the 16th of March, 2017. Criteria for inclusion 
were: 1. Studies of sporadic SVD population (i.e. monogenic causes of SVD such as 
CADASIL were not included), 2. Studies investigating the relationship between DTI metrics 
and cognitive performance, 3. Studies investigating the cognitive domains analysed in the 
current study, 4. Analysis controlling for at least 1 other confounding MRI measure, 5. 
Results involved reporting of standardised く-values or partial correlation coefficients. Where 
a paper reported multiple associations against the same cognitive outcome, the strongest (i.e. 
largest く-value) was included. In cases where a study had published multiple papers based on 
the same participant data, the one which used the most similar metrics to those in the 
presented study was chosen.  
 
Results 
Profile of Participant Variables 
Missing Data: Due to the low sample size (N=1), Site 6 was excluded from all statistical 
analyses. An additional 6 participants were excluded from analysis due to MRI data 
acquisition problems (2 cases from Site 1 due to excessive motion artefacts and corrupted 
data acquisition, and 4 cases from Site 4 where not all imaging sequences were acquired and 
some data were corrupted). Sample size was further reduced by incomplete cognitive data. 
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Verbal Fluency data was absent for one participant, Verbal Memory and NART in another, 
and (only) NART in a third. Sample size was therefore reduced by a further 3 for Verbal 
Fluency comparisons, and by 2 for all other comparisons. Consequently, complete DTI data 
were available in 102 participants, while sample size for main statistical analyses was N= 99 
for testing Verbal Fluency, or N= 100 for all other outcome measures.  
Demographics: Demographics, risk factors and clinical features are shown in Table 1.  
All entry MRI scans were reviewed centrally by a consultant neurologist. All cases fitted the 
MRI inclusion criteria except for two which had WMH graded on the Fazekas scale of <2. 
Both were included in analysis as they had multiple lacunes consistent with severe SVD.  
Cognition: The cognitive profile of the participants, is shown in Figure 1. All 5 cognitive 
domains were significantly impaired compared to control performance levels (p= <.001 in all 
cases except for Verbal Fluency where p= <.05). 
MoCA, QoL and MRI Results: Mean values for MoCA, SSQoL, EuroQoL, and MRI 
parameters are shown in Table 2. Qualitative comparison of histogram measures between the 
WM and NAWM tissue classes showed that the inclusion of WMH in the WM lowered the 
(normalised) peak height of FA and MD, increased the peak value and median of MD, and 
decreased the peak value and median of FA. 
Relationship between MR variables and cognition 
Simple Model Analyses: Full findings are shown in Table 3. FA median and MD peak 
height (in WM and NAWM) were significantly associated with all outcome measures, except 
for NAWM MD peak height with Processing Speed, both NAWM measures with SSQoL, 
and all DTI measures with Verbal Memory. Median FA held stronger associations than MD 
peak height in all cases except for EuroQoL in (all) WM. The directions of these relationships 
demonstrate that higher median FA and MD peak height were associated with better 
cognition or QoL in both tissue classes. There were no marked differences between the 
patterns or strengths of associations for DTI measures taken from within NAWM or the 
whole of the WM. Whole NBV held stronger associations than GM or WM NBV in all cases 
except EuroQoL, where WM was strongest. 
Complex Model Analyses: “Complex Models” were performed to determine which MRI 
variables were independently associated with the outcome measures, and results are shown in 
Table 4. The Variance inflation factors of all models were smaller than 3 and deemed 
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acceptable. Median FA was significantly associated with Global Cognition, Mental 
Flexibility, Verbal Fluency and MoCA in both tissue classes. No other comparisons with DTI 
metrics reached significance. Considering the significant associations, the effect sizes of the 
WM comparisons (as indicated by the く-value) was always descriptively greater than the 
NAWM counterpart. 
The number of lacunes was independently significantly associated with Global Cognition, 
Processing Speed, MoCA and SSQoL in both tissue class models. NBV only maintained a 
significant association with MoCA and EuroQoL (in both tissue class models). WMH lesion 
load was no longer significantly related to any outcome measures. 
Systematic review: Comparison of strength of associations between DTI and 
cognition with that from previous studies 
The search terms identified 230 papers, and after reading these abstracts 37 selected for 
review. An additional 5 papers were identified from reference lists. Eight of these 42 papers 
met inclusion criteria (8,12,29–31,38–40). Supplementary Table 2 details these papers and 
includes key findings from each study. Of note, one of these (39) is a multi-centre study 
across 3 sites using identical 1.5T scanners and acquisition sequences, with MoCA and 
MMSE used as cognitive measures. 
Two of these papers reported 95% confidence intervals (CI) with their く values for 
associations between DTI metrics and cognition (12,38). Comparing the magnitude of the 
DTI-based く values (ignoring direction, as this will be influenced by the specific DTI 
parameter used, which differs between papers) from the presented study for the same 
cognitive domain shows that these fell within, or were higher than these previously reported 
CIs for Global Cognition (our く= .268, previous CIs= -.22 to .06 (12), and -.38 to .02 (38)) 
Executive Functioning (i.e. Mental Flexibility; our く= .306, previous CIs= -.16 to -.06 (12), 
and .05 to .39 (38)), Verbal Fluency (our く= .376, previous CIs= -.21 to -.02 (12)) and Verbal 
Memory (our く= .099, previous CIs= -.28 to -.06 (12)). Only the presented く for Processing 
Speed was lower than a previously reported CI (but only in one of these papers; our く= .058, 
previous CIs= -.24 to -.06 (12), and -.33 to .06 (38)). Conversely, previously reported く 
values from all 8 papers fell within the CIs found in the presented analyses in all instances 
except for one case of Verbal Memory being greater than our CI (previous  く= -.86 (31), our 
CI= -.157 to .355) and one case of Verbal Fluency being lower than our CI (previous  く= -.11 




These analyses are reported in full in the Supplementary Material 
In order to assess any variation across individual sites, analyses were conducted on data from 
each site individually. FA median and MD peak height of each site were compared by one-
way ANOVA, which returned a non-significant finding for each (FA p= .424, MD p= .148). 
Comparison of all outcome measures (i.e. cognitive domains, MoCA and QoL scales) 
between sites by one-way ANOVA and Kruskal-Wallis also showed no significant findings 
(p value range: .192 to .827). 
 “Complex Model” analyses were also repeated in Sites 1, 2 and 3 individually. These were 
repeated in cases where a DTI metric had been shown to have a significant relationship with a 
cognitive domain in the main analyses. These relationships were further visualised by 
scatterplot in all sites, with the 95% CI around the total regression line also included for 
comparison. Complex Model results showed Sites 1 and 2 to have く-values which were 
within, or higher than the 95% CI limits for the same comparison in the main analyses. While 
this was also true for Site 3 in the Global Cognition model, the Mental Flexibility and Verbal 
Fluency models gave a lower く-value than the CI limits. The scatterplot with the “weakest” 
(i.e. flattest) individual-site fit is included here as Figure 2. This shows the relationship 
between WM FA median and Mental Flexibility, with a weak fit for Site 4 (but not Site 3) in 
that its line falls outside of the total CI limits in a manner showing it to be flatter. 
Supplementary Figures 1 and 2 repeat this scatterplot for Global Cognition and Verbal 
Fluency comparisons, and likewise indicate Site 3 (but not Site 4) to have a weak fit in each. 
All other sites show either good fits (i.e. fall completely within the CI limits; see Site 1 in 
Figure 2), or “strong” ones (i.e. fall outside of the total CI limits in a manner showing them to 
have steeper slopes; see Sites 2, 3 and 5 in Figure 2). This suggests that the majority of sites 
do contribute to the main study findings. It is possible that individual cases of small Complex 
Model く-values, and unusually “weak” / “strong” scatterplot fits are due to lack of power 
from low sample sizes. 
 
Discussion 
In this analysis of baseline data from a multi-centre clinical trial of SVD, we found 
associations between DTI metrics and cognition of a similar magnitude to those reported in 
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previous single-centre studies. This provides support for the use of DTI measures as surrogate 
markers in clinical trials of SVD. 
We found that both DTI markers and lacunar infarct count were independently associated 
with Global Cognition and MoCA results. Additionally, DTI markers were independently 
associated with Mental Flexibility and Verbal Fluency, and lacunes with Processing Speed 
and SSQoL. In contrast we found no independent associations between WMH lesion load and 
cognition, and only two for brain volume (with MoCA and EuroQoL). This is in line with 
most previous literature from single-centre studies, which has found weak or absent 
associations between WMH and cognition in patients with severe symptomatic SVD 
(8,29,39). However, it has been previously shown, as we also have, that the presence and 
number of lacunar infarcts (8,38), and the extent of diffuse WM damage assessed on DTI 
(8,12,29,31,38,39), are the strongest predictors of cognitive functioning. Furthermore, both 
have been shown to predict risk of dementia in longitudinal studies (41,42), while lacunes 
and the Apparent Diffusion Coefficient (a diffusion-weighted imaging measure highly similar 
to MD) have also been shown to predict future cognitive decline (43,44). Number of lacunes 
was chosen in the present study instead of lacune volume as it is a more practical measure to 
obtain in a clinical setting, and similar associations with cognitive performance have been 
found between these in a comparable severe SVD population (45). 
Clinical trials of new agents in SVD will need to be multi-centre and if MRI is to be used as a 
surrogate marker it is important to evaluate how the different markers perform in a multi-
centre setting. While research in other neurological disorders such as Parkinson’s (46) and 
Huntington’s (47) disease have shown that DTI markers of disease can be successfully 
applied in a mutli-centre study, there have been few studies addressing this issue in SVD. The 
use of multiple scanners, possibly from different manufacturers, is likely to add noise, and 
may diminish the statistical sensitivity of these metrics.  
PRESERVE is one of the first studies to use advanced MRI imaging as a surrogate marker in 
SVD trials. In this setting we have shown that the magnitudes of associations between DTI 
and cognition are highly comparable to previous, single-centre studies, further validating the 
use of these metrics in this context. Additionally, while WM and NAWM DTI were always 
significantly associated with the same outcomes, the strengths of these associations was 
consistently descriptively greater in WM models. This indicates the simpler process of 
obtaining a WM mask is at least equally valid, and may be more practical in a clinical setting. 
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It should also be noted that previous research has indicated through power calculations that 
DTI parameters could detect change with much smaller sample sizes than lacunes, due to the 
frequency of new lacunes being relatively low (11). This suggests that DTI metrics may be 
the most powerful surrogate marker of the two.  
Examination of individual site data did demonstrate some variation in the strength of 
associations between MR parameters and cognition from different centres, but the majority of 
these effect sizes were within (or greater than) the expected ranges as determined by 95% CIs 
for く-values and regression slopes from the main analyses. DTI metrics and cognition did not 
significantly differ between sites, meaning it is likely that a lack of power due to a low site 
sample size was a contributing factor to the instances where this was not the case. The 
similarity of DTI and cognitive metrics across sites also suggests good comparability between 
the centres involved in this study. With respect to the wider literature however, the authors do 
note that DTI metrics have sometimes been shown to differ in magnitude between 
manufacturers, such as one paper where MD values were found to be systematically higher 
on Siemens vs. Philips scanners (this would not impact peak height of MD as used in the 
presented study, but could affect measures of MD centrality (48)). Another paper (49) 
examined reproducibility of whole brain MD peak height between a 1.5T and a 3T Siemens 
scanner in a sample size of 7 CADASIL patients, which achieved an intraclass correlation 
coefficient of .752 (indicating “good” reliability (50)). A further paper has found scanner 
upgrades to affect DTI after scanning CADASIL patients (51). These findings show caution 
should be used when combining DTI data from different manufacturers or when taking 
measurements over time, and future research may wish to take this into account in analyses. 
These considerations also highlight the importance of conducting multi-centre scanner 
calibration and standardisation of acquisition protocols prior to study commencement, as well 
as on-going quality control checks during the study duration in multi-centre research of this 
nature. 
There were some limitations to this study. There were variable sample sizes across sites, 
meaning the influence of some centres is much stronger than others on our findings. In 
particular, having a greater number of participants scanned on non-Philips hardware would 
have provided more information about the comparability across scanners. The lack of data on 
inter-scanner reproducibility is also limiting and would have been valuable in more closely 
judging the sensitivity of these metrics across sites. It would also have been advantageous to 
acquire a field map with the DTI protocol so that corrections for susceptibility-induced 
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distortions could have been made. However registration to DTI space did appear good, so this 
is unlikely to have caused any major problems. 
To conclude, in a multi-centre study we have shown that DTI metrics and lacune count 
correlate with cognition to a similar degree to that found in single centre studies. Our findings 
support the use of DTI as a surrogate marker of SVD in multi-centre studies.  
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Table 1: Baseline characteristics of the study population. CABG= Coronary Artery Bypass Graft. 
Demographic variable Mean (SD) / Number (%) 
Age, mean (SD) years 68.2 (9.07) 
Male, n (%) 64 (58.7%) 
Premorbid IQ 115.8 (8.12)  
MoCA <26  54 (49.5%) 
Systolic Blood pressure (mmHg) 150 (13) 
Diastolic Blood pressure (mmHg) 85 (12) 
Previous Stroke, n (%) 21 (19.3%) 
Hypercholesterolaemia, n (%) 84 (77.1%) 
Diabetes, n (%) 24 (22.0%) 
Current Smokers, n (%) 16 (14.7%) 
Former smokers, n (%)  40 (37.7%)  
Angina, n (%) 7 (6.4%) 
Myocardial infarction, CABG, or Coronary 
Angioplasty, n (%) 
6 (5.5%) 
Peripheral vascular disease, n (%)  2 (1.9%)  
History of depression, n (%) 20 (18.3%) 
(Other missing data not previously reported; Former smoker = 3; Peripheral vascular 
disease = 1) 
 
Table 2. Mean scores for key individual variables using all available data. SSQoL=Stroke-
Specific Quality of Life; NBV=Normalised Brain Volume; WMH=White Matter Hyperintensity; 
NAWM=Normal Appearing White Matter; WM=(all) White Matter; FA=Fractional Anisotropy; 
MD=Mean Diffusivity. 
Variable Mean (SD), Range 
Cognitive / QoL Variables  
MoCA 24.9 (3.5), 11-30 
SSQoL 190.6 (32.8), 93-244 
EuroQoL 69.3 (19.1), 0-100 
MRI Variables  
NBV (whole brain, ml) 1355.84 (107.70) 
Grey matter normalised volume (ml) 714.49 (73.48) 
White matter normalised volume (ml) 641.35 (70.39) 
WMH volume (ml) 34.74 (22.27) 
WMH lesion load (% brain) 3.41 (2.22) 
Lacunes (number) 4.41 (4.73) 
FA Height x10-3 (NAWM / WM) 3.27 (.26) / 3.24 (.25) 
MD Height x10-2 (NAWM / WM) 1.42 (.21) / 1.33 (.23) 
FA Value (NAWM / WM) .320 (.042) / .311 (.047) 
MD Value mm2s-1 x10-3 (NAWM / WM) .761 (.040) / .762 (.040) 
FA Median (NAWM / WM) .342 (.026) / .335 (.028) 
MD Median mm2s-1 x10-3 (NAWM / WM) .774 (.039) / .787 (.044) 
 
Table 3. Results from linear regression “Simple Model” analyses. All numbers are standardised 
く-values (p-values). Significant relationships are shown in bold while the most strongly 
associated MR variable per outcome, per-category is underlined. NBV=Normalised Brain 
Volume; WMH=White Matter Hyperintensity; NAWM=Normal Appearing White Matter; WM=(all) 
White Matter; FA=Fractional Anisotropy; MD=Mean Diffusivity. 
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Table 4. Results from linear regression “Complex Model” analyses. All numbers are standardised く-values (p-values) [95% standardised く confidence interval], with 
overall model significance being given on the bottom row. Models are separated into those which test NAWM and WM metrics horizontally. Significant associations 
are shown in bold. WMH=White Matter Hyperintensity; NBV=Normalised Brain Volume; NAWM=Normal Appearing White Matter; WM=(all) White Matter; 
FA=Fractional Anisotropy; MD=Mean Diffusivity.  
Tissue class 
model MR Variable Global Cog. Proc. Speed Mental Flex. Verbal Fluency Verbal Mem. MOCA SSQoL EuroQoL 
NAWM 
Whole NBV .134 (.227)  [-.085 : .353]  
.197 (.098) 
[-.037 : .432] 
.112 (.363) 
[-.131 : .356] 
-.041 (.735) 
[-.280 : .198] 
.163 (.213) 
[-.095 : .422] 
.284 (.014) 
[.058 : .509] 
.137 (.323) 
[-.137 : .410] - 
WM NBV - - - - - - - .230 (.030) [.023 : .437] 
WMH Lesion Load -.029 (.775) [-.230 : .172] 
-.126 (.246) 
[-.341 : .089] 
-.009 (.938) 
[-.232 : .215] 
.006 (.954) 
[-.212 : .225] 
.033 (.784) 
[-.204 : .270] 
.116 (.270) 
[-.091 : .323] 
-.100 (.428) 
[-.351 : .150] 
-.144 (.315) 
[-.354 : .125] 
No Lacunes -.251 (.006) [-.429 : -.072] 
-.287 (.004) 
[-.477 : .096] 
-.166 (.099) 
[-.365 : .032] 
-.192 (.057) 
[-.390 : .006] 
-.186 (.082) 
[-.397 : .024] 
-.247 (.009) 
[-.431 : -.063] 
-.245 (.031) 
[-.467 : .-022] 
-.047 (.672) 
[-.266 : .172] 
FA Median .227 (.023) [.032 : .421] 
.038 (.717) 
[-.170 : .247] 
.253 (.022) 
[.037 : .470] 
.333 (.002) 
[.121 : .546] 
.085 (.463) 
[-.145 : .315] 
.244 (.018) 
[.043 : .445] 
.032 (.796) 
[-.211 : .275] 
.196 (.099) 
[-.037 : .428] 
MD Peak Height - - - - - - - - 
Model sig. (p value, 
Adj. R2) <.001, .429 <.001, .334 <.001, .292 <.001, .317 .001, .202 <.001, .392 .029, .108 .004, .164 
WM 
Whole NBV .131 (.236) [-.087 : .349] 
.194 (.103) 
[-.040 : .428] 
.107 (.380) 
[-.135 : .350] 
-.041 (.730) 
[.280 : .197] 
.162 (.215) 
[-.096 : .421] 
.284 (.014) 
[.058 : .509] 
.139 (.316) 
[-.135 : .412] - 
WM NBV - - - - - - - .225 (.033) [.018 : .432] 
WMH Lesion Load .025 (.882) [-.195 : .245] 
-.110 (.359) 
[-.346 : .127] 
.055 (.655) 
[-.189 : .299] 
.075 (.536) 
[-.165 : .315] 
.052 (.693) 
[-.209 : .313] 
.164 (.155) 
[-.063 : .392] 
-.100 (.474) 
[-.376 : .176] 
-.081 (.545) 
[-.347 : .184] 
No Lacunes -.248 (.007) [-.425 : -.70] 
-.285 (.004) 
[-.476 : -.095] 
-.163 (.104) 
[-.360 : .034] 
-.190 (.059) 
[-.388 : .007] 
-.186 (.083) 
[-.396 : .025] 
-.245 (.009) 
[-.429 : -.062] 
-.245 (.031) 
[-.468 : -.023] 
-.047 (.669) 
[-.267 : .172] 
FA Median .268 (.016) [.052 : .484] 
.058 (.621) 
[-.174 : .290] 
.306 (.013) 
[.066 : .546] 
.376 (.002) 
[.140 : .612] 
.099 (.445) 
[-.157 : .355] 
.273 (.017) 
[.049 : .497] 
.026 (.849) 
[-.245 : .297] - 
MD Peak Height - - - - - - - .209 (.112) [-.050 : .468] 
Model sig. (p value, 
Adj. R2) <.001, .433 <.001 .345 <.001, .299 <.001, .319 .001, .202 <.001, .392 .029, .108 .004, .162 
 
 
Figure 1. Cognitive profile of the SVD patient group. This figure shows average, age-matched z 
scores for cognitive indices. Error bars represent +/- 1 standard error of the mean. Index score 

























Figure 2. A scatterplot showing the relationship between WM FA median and Mental 
Flexibility, stratified by study site. In addition to individual site regression lines, the 
regression line for the total is also included with accompanying 95% CI limits (black, 






To assess variation across individual sites, analyses were conducted on data from each site 
individually. Comparison of DTI data by one-way ANOVA between sites gave non-
significant results for both FA median (p= .424) and MD peak height (p= .148). 
Performance in all outcome measures was also compared between sites by Kruskal-Wallis 
(for Mental Flexibility, which was non-normally distributed) and one-way ANOVA (for all 
other metrics). No findings were significant: Global Cognition (p= .661), Processing Speed 
(p= .437), Mental Flexibility (p= .229), Verbal Fluency (p= .827), Verbal Memory (p= .641), 
MoCA (p= .678), SSQoL (p= .192), EuroQoL (p= .272).  
To assess the strength of associations with cognition on DTI measures obtained from 
individual sites, “Complex Model” analyses were repeated in these sites individually. Data 
from Sites 4, 5 and 6 were not included due to small sample sizes. Complex models selected 
for this were ones where the cognitive domain had held a significant association with a DTI 
metric in the main study analysis. The WM DTI model was chosen for replication over the 
accompanying NAWM model due to the former always holding the larger association. 
Complex models were therefore repeated for Global Cognition, Mental Flexibility, and 
Verbal Fluency. The full findings are displayed in Supplementary Table 3. Briefly, this shows 
some variability in the strengths of く-values between sites; notably Site 2 appears to hold 
relatively strong associations (smallest / largest く-value, ignoring direction: .402 / .510) and Site 3 
relatively weak ones (smallest / largest く-value: .047 / -.195). All く-values from Sites 1 and 2, 
and the Global Cognition model for Site 3, fall within the 95% CI reported from the main 
study analysis for the same comparison (see Table 4). However the く-values for Mental 
Flexibility and Verbal Fluency models from Site 3 are lower.  
These relationships are further visualised in Figure 1, and Supplementary Figures 1 and 2, 
which respectively show the relationships between WM FA median and Mental Flexibility, 
Global Cognition and Verbal Fluency, stratified by site while also including Sites 4 and 5. 
The 95% CI around the regression line for the total fit (i.e. ignoring site) is also shown. These 
again show some variability. Notably, with respect to the total regression line, Figure 2 shows 
a “weak” fit for Site 4, and Supplementary Figures 1 and 2 show a “weak” fit for Site 3 (i.e. 
the individual site regression lines lie at least partially outside the total CI limits in a manner 
indicating them to have a flatter slope). All other site lines in all Figures show “good” fit by 
falling either completely within the total CI limits, or outside of them in a manner indicating 
them to have a steeper slope.  
Considering these Figures and the repeated Complex Model analyses, this is suggestive that 
while a minority of comparisons at the individual site level do not appear representative of 
the significant cognitive domain associations reported in Table 4, the majority of site data 
does contribute to the main study finding. Given that neither the cognitive scores or DTI 
metrics differ between sites, that Sites 3 and 4 only have non-representative associations in 
some (but not all) comparisons, and that these sites have low sample sizes, it is likely this is 
due to a lack of power.  
 
Supplementary Table 1. An overview of the exact scanners and sequence parameters used at each site. FOV=Field of View; FLAIR=Fluid Attenuated Inversion 
Recovery 
Site (N) Site 1 (48) Site 2 (29) Site 3 (14) Site 4 (11) Site 5 (6) Site 6 (1) 
3T Scanner(s) Philips Achieva TX Philips Achieva (N=24), 
Philips Achieva TX 
(N=5) 





Philips Ingenia Siemens Prisma 
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No slices: 60 
 
No b0s: 8 
 
Max. Gradient Strength: 
80mT/m 
 
Parallel Imaging Factor: 3 
 
No headcoil channels: 8 
Twice-refocussed 
 
TR = 11500ms 
TE = 93ms 
 
In-plane FOV: 192×192mm2 
 
No slices: 75 
 
No b0s: 2 
 
Max. Gradient Strength 
(Verio/Prisma): 45/80mT/m 
 
Parallel Imaging Factor: 2 
 
No headcoil channels: 32 
DwiSE 
 
TR = 6850ms 





No slices: 60 
 












TR = 9100ms 





No slices: 60 
 












TR = 9500ms 





No slices: 81 
 












Sagittal 3D T1-weighted 
(Isotropic voxel resolution 
1mm3) 
Turbo Field Echo  
 
TR = 8.27ms 
TE = 4.61ms 
 
Field of View 
2402×170mm3 
Turbo Field Echo  
 
TR = 9.81ms 
TE = 4.60ms 
 




TR = 2200ms 




Inversion Time (TI) = 900ms 
Turbo Field Echo  
 
TR = 11ms 
TE = 4.61ms 
 
Field of View 
2402×170mm3 
Turbo Field Echo  
 
TR = 8.53ms 
TE = 4.61ms 
 




TR = 2200ms 






(TI) = 900ms 
Axial T2*-weighted Fast Field Echo  
 
TR = 1800ms 
TE = 20ms 
 




No slices: 51 
Fast Field Echo  
 
TR = 1800ms 
TE = 20ms 
 




No slices: 51 
Spoiled Gradient Echo 
 
TR = 1570ms 
TE = 20ms 
 
Voxel size: 0.942x3mm3 
 
In-plane FOV: 195x240mm 
 
No slices: 50 
Fast Field Echo  
 
TR = 1800ms 







No slices: 51 
 
Fast Field Echo  
 
TR = 1800ms 











TR = 1570ms 








No slices: 50 
Axial FLAIR 







TR = 11000ms 





Voxel size: 0.482×3mm3 
 
No slices: 57 
FLAIR 
 
TR = 11000ms 





Voxel size: 0.482×3mm3 
 
No slices: 57 
Turbo Inversion Recovery 
 
TR = 8000ms 
TE = 124ms 
 
In-plane FOV: 208x230mm 
 
Voxel size: 0.452x3mm3 
 
No slices: 60 
FLAIR 
 
TR = 11000ms 








No slices: 57 
FLAIR 
 
TR = 11000ms 












TR = 8000ms 








No slices: 60 
 
Supplementary Table 2. A summary of results from previous single-centre studies looking at the relationship between DTI metrics and cognition in SVD for 
comparison with the presented study (included at the top). 95% CIs for the く’s have been reported where available. From the present study, “Mental Flexibility” 
has been renamed Executive Functioning, while Verbal Fluency has been kept as a separate domain. This is in order to allow better comparison with previous 
literature. CI = Confidence Interval; FA = Fractional Anisotropy; HDWM = Hemispheric Deep White Matter; MD = Mean Diffusivity; NART = National Adult Reading 
Test; NAWM = Normal Appearing White Matter; NBV = Normalised Brain Volume; PV = Periventricular; RAVLT = Rey Auditory Verbal Learning Test; TMT = Trail 
Marking Test; WM = (all) White Matter; WMH = White Matter Hyperintensity 
Study Study Cohort N DTI Metric Cognitive Measure Model and Additional Variables Finding 
The Presented 
One 





Median Global Cognition (composite score) 
Multiple Linear 
Regression:  
Age, Gender, Site, NART 
IQ, NBV, WMH Lesion 
Load, Lacune No 
く= .268, p= .016 
CI = .052 : .484 
NAWM FA 
Peak Height 
Processing Speed (TMT-A, WAIS 
digit symbol) 
く= .058, p= .621 
CI = -.174 : .290 
WM MD 
Median 
Executive Functioning (i.e. “Mental 
Flexibility”; TMT-B) 
く= .306, p= .013 
CI = .066 : .546 
WM MD 
Median Verbal Memory (RAVLT) 
く= .099, p= .445 
CI = -.157 : .355 
WM FA Peak 
Height MoCA 
く= .273, p= .017 
CI = .049 : .497 
99 WM MD Median 
Verbal Fluency (Verbal Fluency 
Task) 
く= .376, p= .002 
CI = .140 : .612 
(29) Lacunar infarcts and confluent WMH 36 
NAWM MD 
Mean 
Executive Function (Wisconsin 
Card Sorting Task errors) 
Multiple Linear 
Regression:  
Age, Gender, Brain 
Volume, T1 & T2 Lesion 
Load 
く= -.41, p= .046 
(30) 
Vascular risk factors 






Processing Speed (Digit Symbol 
Substitution, Stroop colour naming 
subset task, TMT-A) 
Partial Correlation: 
Age, Gender, WMH 
Lesion Volume 
r= −.27, p= .034 
(31) Lacunar infarcts and confluent WMH 24 
HDWM Mean 
FA 




Age, Gender, WM NBV, 
WMH volume 
く= .56, p= .006 
HDWM Mean 
MD 
Verbal Memory (Wechsler Memory 
Scale Revised) く= -.86, p= <.002 
(12) RUN DMC 503 NAWM MD Mean 
Global Cognition (composite score) 
Multiple Linear 
Regression:  
Age, Gender, Education, 
Depressive symptoms, 
NBV, Lacune No, WMH 
volume 
く= -.18, p= <.01 
CI = -.22 to .06 
Verbal Memory (RAVLT) く= -.18, p= <.01 CI = -.28 to -.06 
Verbal Fluency (Verbal Fluency 
Task) 
く= -.11, p= <.05 
CI = -.21 to -.02 
Executive Function (Stroop task 3) く= -.10, p= <.05 CI = -.16 to -.06 
Processing Speed (Digit Symbol 
Substitution, Paper-Pencil Memory 
Scanning, Stroop reading subset task)
く= -.18, p= <.01 
CI = -.24 to -.06 
(8) SCANS 115 
NAWM RD 
Peak Height 
Executive Function (TMT-B, 
Verbal Fluency, Modified Wisconsin 
Card Sorting)  
Multiple Linear 
Regression:  
Age, Gender, NART IQ, 
NBV, WMH Lesion Load, 
Microbleed No, Lacune No 
く= -.21, p= .046 
NAWM MD 
Peak Height 
Processing Speed (Speed of 
Information Processing, Digit 
Symbol Substitution, Grooved 
Pegboard Task)  
く= -.085, p= .41 
(39) VMCI-Tuscany 76 WM Median MD MoCA 
Partial Correlation: 
Age, Gender, Education, 
WMH rating, Global & 
Temporal lobe atrophy 
ratings 
r= −.28, p= .023 
(38) DANTE Study Leiden 195 
WM MD Mean Global Cognition (composite score) Multiple Linear 
Regression:  
Age, Gender, Education, 
NBV, WMH Volume, 
Microbleed No, Lacune No 
く= -.18, p= .08 
CI = -.38 to .02 
WM RD Mean Processing Speed (Letter-digit substitution) 
く= -.14, p= .17 
CI = -.33 to .06 
WM FA Mean 
Executive Function (interference 
score from abbreviated Stroop, TMT; 
B minus A) 
く= .22, p= .01 
CI = .05 to .39 
(40) Lacunar infarcts and confluent WMH 55 
PV MD Mean Executive Function (TMT, Stroop, Category Fluency) 
Multiple Linear 
Regression (stepwise): 
Age, Gender, Education, 
Depressive State (binary), 
Hypertension (binary), 
NBV, Microbleed No 
く= -.457, p= <.01 
PV MD Mean Verbal Memory (RAVLT) く= -.314, p= .02 
 
Supplementary Table 3. Results of “Complex Model” analyses conducted in each site. For clarity, 
only the association (i.e. standardised く-values, with accompanying 95% CI) of the included 
DTI metric is reported. p values are not reported as varying sample sizes would have a large 
effect on these. All comparisons were made using WM FA median. WM=(all) White Matter; 
FA=Fractional Anisotropy. 
Site Global 







[-.280 : .532] 
.218 
[-.225 : .662] 
.255 







[.077 : .727] 
.510 
[.088 : .931] 
.417 







[-.848 : .457] 
.047 
[-.442 : 535] 
.063 
[-.914 : 1.039] 
 
 
Supplementary Figure 1. A scatterplot showing the relationship between WM FA median and 
Global Cognition, stratified by study site. In addition to individual site regression lines, the 
regression line for the total is also included with accompanying 95% CI limits (black, 




Supplementary Figure 2. A scatterplot showing the relationship between WM FA median and 
Verbal Fluency, stratified by study site. In addition to individual site regression lines, the 
regression line for the total is also included with accompanying 95% CI limits (black, 
dashed line). FA = Fractional Anisotropy; WM = (all) White Matter. 
 
 
 
